Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

TitleGenomic landscape and evolution of metastatic chromophobe renal cell carcinoma.
Publication TypeJournal Article
Year of Publication2017
AuthorsCasuscelli, J, Weinhold, N, Gundem, G, Wang, L, Zabor, EC, Drill, E, Wang, PI, Nanjangud, GJ, Redzematovic, A, Nargund, AM, Manley, BJ, Arcila, ME, Donin, NM, Cheville, JC, R Thompson, H, Pantuck, AJ, Russo, P, Cheng, EH, Lee, W, Tickoo, SK, Ostrovnaya, I, Creighton, CJ, Papaemmanuil, E, Seshan, VE, A Hakimi, A, Hsieh, JJ
JournalJCI Insight
Date Published2017 Jun 15

Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%-10% metastatic incidence. Since extensive chromosomal losses can generate proteotoxic stress and compromise cellular proliferation, it is intriguing how chRCC, a tumor with extensive chromosome losses and a low number of somatic mutations, can develop lethal metastases. Genomic features distinguishing metastatic from nonmetastatic chRCC are unknown. An integrated approach, including whole-genome sequencing (WGS), targeted ultradeep cancer gene sequencing, and chromosome analyses (FACETS, OncoScan, and FISH), was performed on 79 chRCC patients including 38 metastatic (M-chRCC) cases. We demonstrate that TP53 mutations (58%), PTEN mutations (24%), and imbalanced chromosome duplication (ICD, duplication of ≥ 3 chromosomes) (25%) were enriched in M-chRCC. Reconstruction of the subclonal composition of paired primary-metastatic chRCC tumors supports the role of TP53, PTEN, and ICD in metastatic evolution. Finally, the presence of these 3 genomic features in primary tumors of both The Cancer Genome Atlas kidney chromophobe (KICH) (n = 64) and M-chRCC (n = 35) cohorts was associated with worse survival. In summary, our study provides genomic insights into the metastatic progression of chRCC and identifies TP53 mutations, PTEN mutations, and ICD as high-risk features.

Alternate JournalJCI Insight
PubMed ID28614790
PubMed Central IDPMC5470887
Grant List21019 / CRUK_ / Cancer Research UK / United Kingdom
P30 CA008748 / CA / NCI NIH HHS / United States
P30 CA125123 / CA / NCI NIH HHS / United States
T32 CA082088 / CA / NCI NIH HHS / United States